MAPT and Alzheimer disease: This is particularly problematic for imaging and identifying individuals with preclinical AD as tau burden in the medial temporal cortex is beginning to emerge, which is critical for defining the earliest presence of tau pathology and understanding its relationship with decline in cognitive function.